or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    GTHX A G1 Therapeutics, Inc. 0.00
    EXEL B Exelixis, Inc. 0.35
    ACLX C Arcellx, Inc. -0.09
    ELVN C Enliven Therapeutics, Inc. 0.31
    BPMC C Blueprint Medicines Corporation 2.30
    AVBP C ArriVent BioPharma, Inc. -2.39
    PBYI C Puma Biotechnology Inc 2.46
    DAWN D Day One Biopharmaceuticals, Inc. -1.76
    COGT D Cogent Biosciences, Inc. -0.11
    BBIO F BridgeBio Pharma, Inc. 1.04
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Tyrosine Kinase Biopharmaceutical Biotechnology Tyrosine Kinase Receptors Her2 Breast Cancer Clinical Medicine Enzymes Fibroblast Growth Factor Receptor Gastrointestinal Gastrointestinal Stromal Tumor Her2/Neu Mastocytosis Non Small Cell Lung Cancer Organ Systems Receptor Tyrosine Kinase Signal Transduction Solid Tumors Systemic Mastocytosis

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 12.32
    CANC D Tema Oncology ETF 11.33
    CNCR F Loncar Cancer Immunotherapy ETF 8.33
    PBE D PowerShares Dynamic Biotech & Genome 6.77
    BBP C BioShares Biotechnology Products Fund 6.54
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare CANC to PBE Compare CNCR to BBP Compare IDNA to CNCR

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        Nov 21 PBYI PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
        Nov 21 PBYI Puma commences Phase II trial of alisertib for breast cancer treatment
        Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
        Nov 20 PBYI Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
        Nov 20 EXEL Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 DAWN Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Nov 15 BPMC Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
        Nov 15 AVBP ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Tyrosine Kinase Biopharmaceutical Biotechnology Tyrosine Kinase Receptors Her2 Breast Cancer Clinical Medicine Enzymes Fibroblast Growth Factor Receptor Gastrointestinal Gastrointestinal Stromal Tumor Her2/Neu Mastocytosis Non Small Cell Lung Cancer Organ Systems Receptor Tyrosine Kinase Signal Transduction Solid Tumors Systemic Mastocytosis
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags